Geode Capital Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-189,011
| Closed | -$3.47M | – | 4520 |
|
|
2020
Q4 | $3.47M | Buy |
189,011
+7,548
| +4% | +$138K | ﹤0.01% | 2791 |
|
|
2020
Q3 | $3.33M | Buy |
181,463
+6,857
| +4% | +$115K | ﹤0.01% | 2621 |
|
|
2020
Q2 | $2.61M | Buy |
174,606
+10,410
| +6% | +$149K | ﹤0.01% | 2699 |
|
|
2020
Q1 | $2.6M | Buy |
164,196
+7,805
| +5% | +$126K | ﹤0.01% | 2534 |
|
|
2019
Q4 | $2.54M | Buy |
156,391
+5,601
| +4% | +$93.4K | ﹤0.01% | 2866 |
|
|
2019
Q3 | $2.24M | Buy |
150,790
+1,975
| +1% | +$26.6K | ﹤0.01% | 2884 |
|
|
2019
Q2 | $2.46M | Buy |
148,815
+16,812
| +13% | +$275K | ﹤0.01% | 2816 |
|
|
2019
Q1 | $2.28M | Buy |
132,003
+5,936
| +5% | +$108K | ﹤0.01% | 2782 |
|
|
2018
Q4 | $2.23M | Buy |
126,067
+14,621
| +13% | +$248K | ﹤0.01% | 2719 |
|
|
2018
Q3 | $2.02M | Buy |
111,446
+19,423
| +21% | +$398K | ﹤0.01% | 2874 |
|
|
2018
Q2 | $1.8M | Buy |
92,023
+33,938
| +58% | +$636K | ﹤0.01% | 2913 |
|
|
2018
Q1 | $1.02M | Buy |
58,085
+17,280
| +42% | +$316K | ﹤0.01% | 3114 |
|
|
2017
Q4 | $463K | Sell |
40,805
-1,648
| -4% | -$17.2K | ﹤0.01% | 3383 |
|
|
2017
Q3 | $452K | Hold |
42,453
| – | – | ﹤0.01% | 3397 |
|
|
2017
Q2 | $371K | Sell |
42,453
-18,993
| -31% | -$167K | ﹤0.01% | 3460 |
|
|
2017
Q1 | $725K | Buy |
61,446
+1,030
| +2% | +$12.5K | ﹤0.01% | 3159 |
|
|
2016
Q4 | $791K | Buy |
60,416
+3,517
| +6% | +$47.1K | ﹤0.01% | 3101 |
|
|
2016
Q3 | $825K | Buy |
56,899
+1,477
| +3% | +$21K | ﹤0.01% | 3043 |
|
|
2016
Q2 | $664K | Buy |
55,422
+3,170
| +6% | +$50.9K | ﹤0.01% | 3096 |
|
|
2016
Q1 | $974 | Buy |
52,252
+523
| +1% | +$8.67K | ﹤0.01% | 2892 |
|
|
2015
Q4 | $1.11M | Buy |
51,729
+1,580
| +3% | +$33.4K | ﹤0.01% | 2857 |
|
|
2015
Q3 | $849K | Buy |
50,149
+11,889
| +31% | +$296K | ﹤0.01% | 2957 |
|
|
2015
Q2 | $1.44M | Buy |
38,260
+11,226
| +42% | +$362K | ﹤0.01% | 2702 |
|
|
2015
Q1 | $850K | Buy |
27,034
+10,009
| +59% | +$270K | ﹤0.01% | 2950 |
|
|
2014
Q4 | $219K | Buy |
+17,025
| New | +$261K | ﹤0.01% | 3546 |
|
Geode Capital Management's CBMG Position: Q1 2021 in Review
Geode Capital Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q1 2021, closing a stake of 189,011 shares — an estimated $3.47M sold.
Geode Capital Management first reported a position in CBMG in Q4 2014 and held it in 25 quarters. The position peaked at $3.47M in Q4 2020. 0 funds tracked by Wall St. Rank hold CBMG as of Q1 2021.
- Geode Capital Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q1 2021 after selling out during the quarter.
- Geode Capital Management sold 189,011 Cellular Biomedicine Group, Inc. shares in Q1 2021, an estimated $3.47M.
- Geode Capital Management first reported a position in Cellular Biomedicine Group, Inc. in Q4 2014 and held it in 25 quarters.
- Geode Capital Management's Cellular Biomedicine Group, Inc. position peaked at $3.47M in Q4 2020.
- 0 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q1 2021.
Based on Geode Capital Management's 13F filing for Q1 2021, filed 12 May 2021.